Uncategorized

RELIEF THERAPEUTICS Holding SA is pleased to announce the availability of the newest PKU GOLIKE BARs ® in Europe.

Oxford Nanopore Technologies and Dutch start-up Cyclomics announced the ‘developer access’ of a new research workflow: the world’s first nanopore sequencing-based solution for ultra-sensitive detection of circulating tumour DNA.

Embolx, Inc. announced the signing of a distribution agreement with Cardiva Italia SRL.

Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

OKYO Pharma Limited announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website.

Anaveon announced the first patient dosed with ANV419 in the OMNIA-2 study – a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone.

Addex Therapeutics Ltd announced that it will participate in the following conferences during the first half of 2023.

Akeso Inc. released its 2022 annual report. During the reporting period, the company enjoyed booming business development and made breakthrough progress in drug innovation and development, commercialization and internationalization.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.

Sean Martin is stepping up as chief medical officer of the New York-based insurer, after Oscar’s old CMO left to become CMO of L.A. Care Health Plan in December.